

# RESPIRI



A Breath of Fresh Ideas

## SHAREHOLDER UPDATE

13 November 2018

Conference call 9.30am AEDT  
Tel: 1800123 296  
Conference ID: 2797829



**We breathe in,  
We breathe out,  
We breathe deep.**

But for 334 million of our fellow human beings, breathing is not the easy instinctive, life-affirming action the rest of us don't even think twice about.

*Anything but!* To people with asthma the simple act of breathing can be a choking, gasping, drowning, suffocating daily ordeal.

Asthma **can't be cured**, but with supported self-management, it **can be controlled**.  
Introducing **Respiri**, a revolutionary 'early warning system' to pinpoint the signs of a coming asthma attack so appropriate action can be taken. Let's stop the attack before it happens.

**Respiri's mission is to profoundly improve quality of life for millions of families affected by asthma, and dramatically reduce hospital admissions and the economic burden of asthma.**

**How? With a Breath of Fresh Ideas.**

# CONFERENCE CALL AGENDA


## CEO | INTRODUCTION



### PROFESSOR BRUCE THOMPSON

Chair, Australian Medical & Scientific Advisory Board

[London meeting](#) | [Study planning](#)



### MARIO GATTINO

Chief Executive Officer & Director

[Delivering on stated milestones](#)



### WANI WALL

Chief Customer Experience & Communications Officer

[Go to Market](#) | [Customer engagement strategy](#)

## CEO | NEW MILESTONES SET

[Clear roadmap to product launch](#)

## Q&A

In the interests of providing shareholders with the most comprehensive information within the limited timeframe, questions are invited in writing through out the presentation in real time.

Questions will be prioritised for response and we will follow up directly on those we may not have time to cover off after the call.

The CXO has produced a **Product Development Update** video now available via the link below featuring **Grey Innovation Director, Jefferson Harcourt** and **Two Bulls Partner, Evan Davey**.



**GREY** INNOVATION  
TECHNOLOGY COMMERCIALISATION

 **twobulls**



# UK MEDICAL & SCIENTIFIC ADVISORY BOARD

STUDY PLANNING MEETING | ROYAL COLLEGE OF PHYSICIANS | LONDON | 29 OCTOBER 2018





# BUILDING EVIDENCE TO DEMONSTRATE THE CLINICAL RELEVANCE OF RESPIRI TECHNOLOGY

*Respiri has the potential to transform the clinical asthma pathway, with the potential to detect when patients are unwell, or importantly, about to become unwell, so additional treatment can be taken to avoid any serious deterioration.*

**Professor Anoop Chauhan, Portsmouth Hospitals  
NHS Trust**

A successful launch is dependent on clinical acceptance of Respiri's technology. When patients ask their GP what they think of Wheezo, we need the GP to know about the product, understand the science behind it, the meaning of the wheeze rate value and the role it can play in the patient's asthma management plan.

Further, key bodies such as Asthma UK and Asthma Australia will need to endorse the technology and incorporate it into current management guidelines.

Many of the UK's leading asthma experts joined us to consider the evidence requirements for Wheezo to be clinically accepted and ultimately become a standard of care for patients living with asthma.

# DELEGATES

**Dr Mark Levy | Co-Chair**  
Harrow CCG

**Professor Aziz Sheikh**  
Usher Institute / Asthma UK Centre for Applied Research

**Professor Anoop Chauhan**  
Portsmouth Hospitals NHS Trust

**Dr Louise Fleming**  
Royal Brompton Hospital

**Professor Jonathan Grigg**  
Queen Mary University of London

**Dr Katy Pike**  
UCL Great Ormond Street Institute of Child Health

**Dr Paul Seddon**  
Royal Alexandra Children's Hospital Brighton

**Professor Simon Godfrey**  
Hadassah Medical Centre

**Professor Bruce Thompson**  
The Alfred Hospital, Monash University

**Mario Gattino, Dr Samaneh Sarraf, James Brown, Oli Sylvester, James Cockerill** (Origin Health)

- WHAT IS CLINICAL RELEVANCE OF TECHNOLOGY AND WHEEZE RATE?
- WHAT IS THE VALUE OF THE TECHNOLOGY TO HEALTHCARE PROFESSIONALS AND PATIENTS/PARENTS?
- WHAT IS THE IMPACT OF THE TECHNOLOGY ON THE WIDER HEALTH SERVICE?

*An exciting innovation that could potentially be of great value, especially in the wheezy pre-school child.*

**Dr Paul Seddon**  
Royal Alexandra Children's Hospital Brighton



# PRIORITY STUDIES

1. Comparison Study	2. Correlation Study	3. Longitudinal Health-Outcomes Study
To demonstrate that Wheezo is as good as a doctor's stethoscope	To assess the correlation between wheeze rate and a relevant clinical measure of lung function e.g. FEV <sub>1</sub> and symptom score	To assess the outcomes of patient given Wheezo for use at home and the impact on medical resources

1. Short term study can be initially conducted in Australia as ethics approval process much quicker than UK. Study outcomes would be published to coincide with Wheezo launch.
2. Short term head to head comparison of wheeze rate with other lung function measure could be conducted as part of, or as a follow-on to the comparison study. Two possible settings identified; acute care and primary care. As for study 1, ethics approval quicker in Australia.
3. Longitudinal study key questions: Can Wheezo predict increase in symptoms, predict exacerbations and have a positive impact on healthcare resources? **Important outcomes: Does regular use of Wheezo improve quality of life, sleep, activity participation, school attendance and attack frequency?**



# FEEDBACK ON POTENTIAL CLINICAL VALUE

## Objective Measure

May help to provide additional piece of objective data on how well asthma is controlled\*

## Improved classification

Improved classification of severity of symptoms – which would guide therapy in acute attacks

## Biofeedback to patients

Allow them to make connections between triggers/seasons/locations etc. and their health

## Improved recognition of risk

For clinicians, patients and parents

## Overnight monitoring

Could be particularly promising

## Big data


For clinicians/researchers there would potentially be benefit in collecting big data via connection to an app and collection of other passive data e.g. location, time, date, sex, age etc.

\*Particularly if we can demonstrate clear relationships to established measures of lung function, current asthma and status of airway patency




# NEXT STEPS

- 115 of 130 devices manufactured by SRX available for clinical studies and user testing 8 February 2019
- Plan to conduct study 1 in Australia February 2019. (Lower risk ethics approval). 100 patients over 6 week period at sites to be announced
- UK studies driven by investigator group once protocols signed off. May take a little longer and have a variation to Australian studies to capture new data
- Multiple funding options in Australia & UK beyond company if science is interesting / compelling



## DELIVERING ON MILESTONES THROUGH 2018CY

- Aligned with our mission
- Executing the plan







# + HUGE GLOBAL ASTHMA MARKET

COMPARED TO DIABETES 387M (2014) PROJECTED TO 471M (2035)

There has been a sharp increase in the global prevalence, morbidity, mortality, and economic burden associated with asthma over the last 40 years, particularly in children. Approximately 330 million people worldwide currently have asthma, and its prevalence increases by 50% every decade.

Asthma is underdiagnosed and undertreated. **The increasing number of hospital admissions for asthma, which are most pronounced in young children, reflect an increase in severe asthma, poor disease management, and poverty.**

Worldwide, approximately 250,000 deaths annually are attributable to asthma.

- **334 million people** have asthma (**400 million** by 2025)
- **14% of the world's children** experience asthma symptoms
- **8.6% of young adults** experience asthma symptoms
- **Approximately 250,000 people die** prematurely each year from asthma. Almost all these deaths are avoidable



**100**  
MILLION



**30**  
MILLION



**25**  
MILLION

World Map of the Prevalance of Clinical Asthma

Source: Global Burden of Asthma; GINA





**5**  
MILLION



**2**  
MILLION



**600**  
THOUSAND



# COMPETITIVE LANDSCAPE

Few players & limited innovation compared to glucose monitors & heart/BP monitors



## Asthma Wheeze Monitor

No objective wheeze measurement devices on the market suitable for children who cannot perform lung function tests\*

(Disruptive technology –  
**Acoustic Respiratory Monitoring (ARM™)**)

## Lung Function Tests

Cohero Health Spirometry, Wing Spirometry, Peak Flow  
Manufacturers including digital (difficult to use, patient interpretation & data unreliable)

## Smart Inhalers / Compliance

Adherium, Propeller Health, Gecko Health Innovations (TEVA Pharmaceuticals), Cohero Health, 3M (probably most activity, lack of compliance a major issue)




Fevipirant (Novartis) – first new drug treatment in asthma for 20 years.  
Biological agent, reduces the severity (not a cure), most likely reserved for severe asthma patients.

\*as far as the company knows

# PRIMARY TARGET MARKET

(25 – 30 % OF TOTAL ASTHMA POPULATION)



## THE BURNING PLATFORM

**Asthma is the leading cause of hospitalisation in children.**

Young children cannot use lung function tests and peak flow meters, and their parents and carers have difficulty communicating wheezing episodes to their physician.

This represents some of the most costly patients to the health system.

**Health Authorities / Insurers are highly motivated to address this now**



Burden of disease, measured by disability Adjusted life years (DALYs) per 100,000 population Attributed to asthma by age group and sex. Global Population 2010 Global Asthma Report 2014



**“mHealth solutions are amongst the highest priority for research to optimise asthma management and prevent asthma attacks.”**

European Asthma Research and Innovation Partnership



# IMAGINE IF YOUR DOCTOR & THEIR STETHOSCOPE WAS WITH YOU 24/7

Respiri technology listens to your breath sounds and detects wheeze as well as, if not better, than a doctor. The doctor's assessment of the presence of wheeze and its severity is based on their ears and their interpretation of what they're hearing. It's anecdotal, but a doctor will tell you that auscultation is more of an art than a science and they trust their own ears above all others.

Respiri's wheeze detection algorithm provides an objective measure of this typical asthma symptom and it can hear frequencies the stethoscope can't.

**For parents of a child with asthma, we offer the peace of mind of a 'doctor in the house with a stethoscope' 24/7.**



# PERSONAL ASTHMA COACH



Using **machine learning**, we can correlate relevant events with wheeze rate, creating an even more compelling product for the proactive management of asthma. **It's a personalized early warning system.**

As the user is performing a wheeze rate measurement, the device connects to the Respiri backend and requests the current weather, pollen and pollution conditions in the user's location. Once the wheeze rate is determined, it will be combined with the atmospheric conditions, data from Apple Health/GoogleFit (such as heart rate) and time of day. It will also take into account other symptoms and triggers entered by the user.

This personal data is then fed into the machine learning model included in the app to determine when there is a heightened risk of asthma symptoms and alerts the user if there is.

# ALL ABOUT ENGAGEMENT



We're developing an app experience to make wheeze monitoring fun for kids and their parents/carers. App stickiness is crucial to drive regular use for education, to help prevent asthma flareups and to capture personal data for machine learning purposes.







# CUSTOMER JOURNEY



**Asthma Action Plan**  
For use with a Puffer and Spacer

Name: \_\_\_\_\_  
Date of birth: \_\_\_\_\_  
Confirmed Triggers: \_\_\_\_\_

Photo: \_\_\_\_\_

**Asthma Foundation VIC**  
Child can self-administer if well enough.  
Child needs to pre-medicate prior to exercise.  
Face mask needed with spacer.

**ALWAYS** give adrenaline autoinjector **FIRST** and then asthma reliever puffer if someone with known asthma and allergy to food, insects or medication has **SUDDEN BREATHING DIFFICULTY** (including wheeze, persistent cough or hoarse voice) even if there are no skin symptoms.  
Adrenaline autoinjector prescribed: ☐ Y ☐ N Type of adrenaline autoinjector: \_\_\_\_\_

**SIGNS AND SYMPTOMS**

**MILD TO MODERATE**

- Minor difficulty breathing
- May have a cough
- May have a wheeze

Other signs to look for: \_\_\_\_\_

**SEVERE**

- Cannot speak a full sentence
- Sitting hunched forward
- Tugging in of skin near chest/ribs
- May have a cough or wheeze
- Obvious difficulty breathing
- Letargic
- Some tummy (young children)

**LIFE-THREATENING**

- Unable to speak or 1-2 words
- Collapsed / Exhausted
- Gurgling for breath
- May no longer have a cough or wheeze
- Droney / Confused / Unconscious
- Blue discoloration (blue lips)

Emergency Contact Name: \_\_\_\_\_  
Work Ph: \_\_\_\_\_  
Home Ph: \_\_\_\_\_  
Mobile Ph: \_\_\_\_\_

Plan prepared by Medical or Nurse Practitioner: \_\_\_\_\_  
Respiri asthma reliever medication dispenser on the plan to be used according to the plan to be used.

**Blue/grey reliever medication is unlikely to harm, even if the person does not have asthma.**

**ASTHMA FIRST AID**

For Severe or Life-Threatening signs and symptoms, call for emergency assistance immediately on Triple Zero "000". Mild to moderate symptoms do not always present before severe or life-threatening symptoms.

1. Sit the person upright.
  - Stay with the person and be calm and reassuring.
2. Give \_\_\_\_\_ separate puffs of Alomic, Asmol or Ventolin.
  - Shake puffer before each puff.
  - Put 1 puff into the spacer at a time.
  - Take 4 breaths from spacer between each puff.
3. Wait 4 minutes.
  - If there is no improvement, repeat step 2.
4. If there is still no improvement call emergency assistance.
  - Dial Triple Zero "000".
  - Say "ambulance" and that someone is having an asthma attack.
  - Keep giving \_\_\_\_\_ puffs every 4 minutes until emergency assistance arrives.

Commence CPR at any time if person is unresponsive and not breathing normally.

**Blue/grey reliever medication is unlikely to harm, even if the person does not have asthma.**

Respiri asthma reliever medication dispenser on the plan to be used according to the plan to be used.

**Blue/grey reliever medication is unlikely to harm, even if the person does not have asthma.**

Respiri asthma reliever medication dispenser on the plan to be used according to the plan to be used.



**Today** peak flow meters are recommended for symptom monitoring along with paper diaries for recording symptoms and triggers. Peak flow meters are not recommended for children, are difficult to use and unreliable. Parents rely on paper records and subjective observations for their doctor. It's stressful!

**2019** Respiri offers an easy-to-use, passive smartphone enabled digital solution with objective symptom monitoring and electronic diary correlating atmospheric conditions with other relevant data including inhaler use. Objective data is stored in the cloud for sharing with doctors. It provides alerts when conditions are threatening and removes the guesswork!

**2021** Respiri users can spot check using their 30 second symptom monitor during the day and then rely on the overnight monitor to provide peace of mind. Important overnight data can help inform treatment plans.

**Future Continuous Symptom Monitoring as available for diabetes patients in Continuous Glucose Monitoring (CGM) ++**

# MAJOR MILESTONES & INFLECTION POINTS

Gen II - Wheezo	2018	
Initial functioning demonstration quality prototype for technology demonstration purpose with partner & investors	Q2 ✓	
Fully functional medical device quality prototype with design completed	Q3 ✓	
Attend major industry tradeshows and healthcare conferences to showcase and generate interest for AirSonea Gen II with investors, customer and potential partners	Q3 ✓	
Manufacturing package and limited production of verification units by contract manufacturer	Q3 ✓	
One or more Memoranda of Understanding (MOU) or Letters of Intent (LOI) for collaboration will be established with targeted development & commercialisation partners to advance Wheezo	Q3 ?	
Final design updates and verification testing and Ideally handover to preferred manufacturing partners in key target regions. (Initial manufacturing planned to take place in Australia, with export to target market(s))	Q4 ✓	
Finalise planning and launch a significant pilot program in a major market (e.g. UK) to establish value proposition of AirSonea Gen II. (Observational community based studies compared to current practice)	Q4 ✓	
Regulatory approvals processes (ongoing defined by requirements of health agencies: CE, TGA, FDA )	Q3/Q4 ✓	

# \$3.0M CAPITAL RAISE (April 18) | USE OF FUNDS

Gen II - Wheezo	2018
Development of Android platform to parity with existing iOS platform, in effect doubling size of target market at launch (based on current distribution of smartphones)	✓
Appointment of Quality Assurance & Regulatory Manager on a contract basis to establish our QMS and ISO 13485 certification and facilitate regulatory approvals in target market launch markets	✓
Early collaboration with identified Australian manufacturer to facilitate a smooth transfer from developers to high capacity manufacturing capabilities (e.g. purchase of new tooling, bulk quantities of components, batch testing etc.)	✓
Review and expansion of our multi-facted intellectual property by registering new patents, adding to our existing trade secrets and proprietary information, trademarks and copyright, ensuring highest barriers to competition in the geographies where we choose to launch (initial review phase completed, ongoing in line with development and new IP)	✓
Planning launch strategy – e.g. market research, online platform strategy, consumer and media campaigns, promotional materials, partnerships, distribution, brand ambassadors, asthma association support/collaboration	✓
Appointment of a UK based Business Development Manager on a contract basis to facilitate and expedite observational, real-world community studies of Wheezo compared to current practice (similar appointment in Singapore)	✓
Progress development of the overnight monitor which will be a major addition to the product portfolio, with the company ensuring the timing of finalisation and planned launch follows smoothly after the successful launch of Wheezo	✓





# ISO 13485 CERTIFICATION & REGULATORY APPROVALS

## QMS:

- Procedures are drafted; expect to have all QMS documents and records demonstrating conformance to 13485 finalised by end November.
- Technical File –design/risk analysis finalised. Usability, biocompatibility etc. commencing for completion by end November.

## CE Marking:

- Application following 12 week Safety and EMC testing using production tool samples (Delivery by contract manufacturer (SRX) of 15 units for Safety and Compliance 21 December 2018)
- TGA, Australia, HSA, Singapore to follow 6 – 8 weeks after CE mark received
- Stage 1 Notified Body regulatory audit November 2018
- FDA 510(k) clearance submission document preparation to commence early 2019 (there are differences, but heavy lifting done on CE and supporting Amazon web servers architecture by Two Bulls is HIPAA compliant\*).

\***Health Insurance Portability and Accountability Act**, a US law designed to provide privacy standards to protect patients' medical records and other health information provided to health plans, doctors, hospitals and other health care providers.

# INTELLECTUAL PROPERTY MULTI-FACETED



Copyright  
(software coding)

Trade Marks  
(branding)




Proprietary Information / Trade Secrets  
(algorithms, know-how, data)

Patents  
(systems, methods of diagnosis, related technologies)


## Wheezo | Lead home monitoring product

- Over the counter (Class IIA) device for home use
- Detects, quantifies, and measures wheezing using ARM™ Algorithm
- Bluetooth connectivity to mobile devices
- Results uploaded to cloud for review by patient's doctor/anonymised data stored for big data purposes
- **New IP in major system technology update**

# RESPIRI



A Breath of Fresh Ideas



RESPIRI



# OVERNIGHT MONITORING DEVICE

Patients who wheeze at night are not well-controlled and their treatment should be stepped up (GINA/NHLBI).



Based on the company's original Wholter™ product, Respiri is developing a wireless wheeze and cough detector for nocturnal asthma assessment. The ability to evaluate the degree of asthma control in patients who wheeze at night will be an invaluable tool for physicians making treatment decisions and assessing therapy response.

Sleepless nights are common for parents of children with asthma. Respiri's solution will provide peace of mind that has never been possible before with continuous monitoring that will provide an alarm should there be an exacerbation.

- Wheezo R&D provides technology foundation for updated sensors, enhanced algorithms, noise cancellation, Bluetooth connectivity and data streaming
- Utilizes Wheezo machine learning model





Powered by  AdvaMed



# INAUGURAL EXHIBIT @ KEY US EVENT



**3,000**

ATTENDEES



**30**

COUNTRIES



**40**

STATES



**125**

EXHIBITORS



**80+**

SESSIONS AND  
PRESENTATIONS



**250+**

SPEAKERS

Wheezo technology applauded by hundreds of delegates who visited the booth.

No other new product in the asthma space.

# POTENTIAL PARTNERS

Many potential partners, but none are 'perfect'. They want certainty and de-risking to replace internal candidates.

**VS**

We want to maintain some control and commitment they will priorities our products.

## MOBILE HEALTH DEVICES

Apple, Samsung, Xiaomi, Sony, Huawei, FitBit, Garmin, Jawbone, iHealth Labs

## DIGITAL PLATFORMS

Google, Microsoft, Qualcomm, Neusoft, Yahoo

## MEDICAL DEVICE COMPANIES


Philips, Omron, ResMed, GE Healthcare, CareFusion, Vectura, Propeller Health, Alere, Care Innovations, Dexcom, Medtronic, 3M

## TELEHEALTH

AT&T, Verizon, Telstra, Optus

## BIG PHARMA

GSK, Astra Zeneca, Schering-Plough, Boehringer Ingelheim, Novartis, Teva




Medical quality device completed Sept / Oct  
Now we can go hard; clear we will be first to market

# GO TO MARKET CUSTOMER ENGAGEMENT STRATEGY



RESPIRI



A Breath of Fresh Ideas



# PHASE 1 SURVEY REVEALS DEMAND

## PARENTS OF CHILDREN WITH ASTHMA (UNDER 14)

- Product naming survey of 1758 parents of children with asthma across 3 geographies
- 632 responders
- UK 216, AUS 209, SGN 207
- **61% provided email addresses as registration of interest – extraordinary, especially for first contact**
- Average email opt-in rate is 1.95% and the top 10% of marketers average a 4.77% opt-in rate
- Supports findings from historic research; there is an **unmet need for objective symptom monitoring**
- 93% would buy online
- **32% would spend \$350 on this product**



“Great idea, and keeping track of your progress, then being able to show your doctor – genius.”

*Customer Verbatim, UK*

“Sounds like a Godsend to parents like me... Love the concept and can't wait to be able to purchase one.”

*Customer Verbatim, Australia*

“I'm very excited that big data helps to predict the attack. I will buy whatever it takes.”

*Customer Verbatim, Singapore*

# PHASE 2 | DIGITAL LED CUSTOMER ENGAGEMENT

## Building brand Wheezo

- 1 in 9 Australians affected by asthma
- **Primary target - 600,000 children/young people affected by asthma**
- 39,448 hospitalisations for asthma in 2015/16
- **51% of asthma hospitalisations were children 0 – 14**
- In 2020, the number of Facebook users in Australia is expected to reach **11.23 million**

RESPIRI 



It's time to start  
the conversation  
with 'connected'  
parents and build  
the  
Respiri customer  
database





# REACHING OUR TARGET MARKET

Word of mouth is still the primary influencer on purchase decisions, 76% of respondents identifying recommendations from friends, family and acquaintances as having a high or medium influence on their buying decisions.

82% of millennial dads turn to guidance on key parenting topics like preparing meals, using a product or assembling gear

We spend 21% of our digital entertainment time consuming social media, which is even higher among women, who spend 25% of their digital entertainment time on social media compared with 17% for men.

For Millennials in particular, recommendations from those within their social circles (75%) and advertising on social platforms and online reviews from those they do not know (66%), outstrip the influence of TV advertising (61%).

# AUSTRALIAN PILOT

Prior to kicking-off a full multinational marketing strategy, an initial digital only pilot will be deployed to gauge initial demand for Wheezo in Australia creating an early groundswell. UK and other markets will follow.

## Campaign Objective:


- Gauge latent demand for the product and **capture pre-registrations ahead of market launch**
- Capture direct feedback from customers – what do they want, where do they want to purchase?
- Potential for pre-orders.

## Pilot Considerations:

- Digital led with PR support for most cost-effective reach
- Leverage local KOL supporters of Respiri
- Drive pre-registrations (no financial commitment) amongst parents of children with asthma – **BUILD CUSTOMER DATABASE**
- Nurture leads with monthly updates through to in-market availability
- Develop Facebook community and support with paid Facebook/Instagram advertising
- Consider engagement with influencers to build authenticity and intimacy with audience
- Engage Respiri Ambassadors – e.g. Ian Thorpe started swimming to help his asthma
- Share the vision for future product development eg. AI, overnight monitoring, wearables etc



# RESPIRI



A Breath of Fresh Ideas





# NEW MILESTONES | NEWSFLOW

Wheezo Commercialisation	2018/19 CY
Manufacturing transfer Grey Innovation – SRX for build of 15 x field units for safety/compliance test/Respiri ISO 13485 Stage 1 Audit	Q4/18
External Safety and Compliance Testing (15 field units and packaging produced by Respiri)	Q1/19
Respiri ISO13485 Stage 2 Audit	Q1/19
Safety/compliance test Lab Report – technical file completion and submission to Notified Body (NB) EC certificate	Q1/19
Notified Body review of technical file – European CE clearance for sale in UK and Europe (1 – 3 months). Compile FDA 510 (k) technical file	Q1-Q2/19
Soft Launch - Australian customer engagement pilot ‘Register you Interest Campaign’ – (Respiri and LIDA Australia nurture & grow customer database) Components include social media platforms, paid media, public relations, ambassador program, KOL program, Asthma Australia endorsement, user test program, pre-orders, organic market research to determine optimum sales channels	Q4/18-Q1/19
Australian and UK studies 1 & 2 executed for publication. HCP communications program commences.	Q1-Q2/19
Launch UK and Singapore customer engagement program with Australian assets/learnings (LIDA Australia & UK)	Q1-Q2/19
Australian TGA and Singapore HSA submissions off back of CE mark	Q2/19
Wheezo available for sale in UK, Australia and Singapore – launch activity	Q1-Q2/ 19
Tested Turn Key Launch Program customised by market for EU roll out	Q3 -Q4/19

**We breathe in,  
We breathe out,  
We breathe deep.**

But for 334 million of our fellow human beings, breathing is not the easy instinctive, life-affirming action the rest of us don't even think twice about.

*Anything but!* To people with asthma the simple act of breathing can be a choking, gasping, drowning, suffocating daily ordeal.

Asthma **can't be cured**, but with supported self-management, it **can be controlled**.  
Introducing **Respiri**, a revolutionary 'early warning system' to pinpoint the signs of a coming asthma attack so appropriate action can be taken. Let's stop the attack before it happens.

**Respiri's mission is to profoundly improve quality of life for millions of families affected by asthma, and dramatically reduce hospital admissions and the economic burden of asthma.**

**How? With a Breath of Fresh Ideas.**





A Breath of Fresh Ideas

THANK YOU



## Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiro's current expectations, estimates and projections about the industry in which Respiro operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiro, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiro cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiro only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiro will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

RESPIRI



**CONTACT:**

**MARIO GATTINO**  
CEO & Director

+61 457 722 055  
+61 3 9653 9160  
[mario@respiri.co](mailto:mario@respiri.co)

**WANI WALL**

Chief Customer Experience & Communications Officer (CXO)

+61 419 574 097  
+61 3 9653 9160  
[wani@respiri.co](mailto:wani@respiri.co)

[respiri.co](http://respiri.co)

RESPIRI LIMITED [ASX:RSH]  
Level 27 101 Collins Street Melbourne  
Victoria 3000 Australia

Registered office: 10/446 Collins Street Melbourne Victoria 3000 Australia